3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Multiple Myeloma
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Lymphoma
19
Leukemia, Myeloid, Acute
18
Myelodysplastic Syndromes
17
Lymphoma, Non-Hodgkin
14
Neoplasms, Plasma Cell
12
Leukemia
12
Neuroblastoma
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Large B-Cell, Diffuse
9
Hodgkin Disease
9
Recurrence
7
Melanoma
7
Lymphoma, Mantle-Cell
7
Hematologic Neoplasms
7
Burkitt Lymphoma
7
Sarcoma
6
Ovarian Neoplasms
6
Myeloproliferative Disorders
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Follicular
6
Sarcoma, Ewing
5
Neoplasm Metastasis
5
Medulloblastoma
5
Lymphoma, B-Cell, Marginal Zone
5
Liver Neoplasms
5
Wilms Tumor
4
Rhabdomyosarcoma
4
Retinoblastoma
4
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
Melphalan
×
Clear all
NCT02660281
2021-11-03
HaploOnly
University of Rochester
Phase 1
Completed
74 enrolled